Cough in Chronic Obstructive Pulmonary Disease

Cough: Causes, Mechanisms and Therapy

Volumn , Issue , 2008, Pages 125-135

  Chung, Kian Fan ^a   Calverley, Peter M A ^b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Aetiological factors; COPD; Cough reflex sensitivity; Macrophages; Pathophysiological changes

Indexed keywords

EID: 20444409408     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470755846.ch13     Document Type: Chapter

References (79)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
3. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-8.
4. Peto R, Speizer FE, Cochrane AL, Moore F, Fletcher CM, Tinker CM et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983; 128:491-500.
5. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333-8.
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22.
7. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-64.
8. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-7.
9. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160: 1683-9.
10. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166:329-32.
11. Eriksson S. A 30-year perspective on alpha 1-antitrypsin deficiency. Chest 1996; 110: 237S-42S.
12. Sandford AJ, Weir TD, Spinelli JJ, Pare PD. Z and S mutations of the alpha1-antitrypsin gene and the risk of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 1999; 20: 287-91.
13. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-73.
14. Pilette C, Godding V, Kiss R, Delos M, Verbeken E, Decaestecker C et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 185-94.
15. Wanner A. Clinical aspects of mucociliary transport. Am Rev Respir Dis 1977; 116: 73-125.
16. Di SA, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-85.
17. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, Der Mark TW, Koeter GH et al. Ongoing airway inflam- mation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-8.
18. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Resp J 2001; 18 (Suppl. 34): 50s-59s.
19. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995; 152: 1666-72.
20. Saetta M, Turato G, Baraldo S, Zanin A, Braccioni F, Mapp CE et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 2000; 161:1016-21.
21. Confalonieri M, Mainardi E, Della PR, Bernorio S, Gandola L, Beghe B et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease [see comments]. Thorax 1998; 53: 583-5.
22. Yoshioka A, Betsuyaku T, Nishimura M, Miyamoto K, Kondo T, Kawakami Y. Excessive neutrophil elastase in bronchoalveolar lavage fluid in subclinical emphysema. Am J Respir Crit Care Med 1995; 152: 2127-32.
23. Abboud RT, Fera T, Johal S, Richter A, Gibson N. Effect of smoking on plasma neutrophil elastase levels. J Lab Clin Med 1986; 108: 294-300.
24. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990; 85: 682-9.
25. Smallman LA, Hill SL, Stockley RA. Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine proteinase effect. Thorax 1984; 39: 663-7.
26. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-7.
27. Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147: 301-6.
28. Turato G, Di Stefano A, Maestrelli P, Mapp CE, Ruggieri MP, Roggeri A et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995; 152: 1262-7.
29. Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-9.
30. Petty TL, Silvers GW, Stanford RE. Mild emphysema is associated with reduced elastic recoil and increased lung size but not with air-flow limitation. Am Rev Respir Dis 1987; 136: 867-71.
31. Mead J, Turner JM, Macklem PT, Little JB. Significance of the relationship between lung recoil and maximum expiratory flow. J Appl Physiol 1967; 22: 95-108.
32. Matsuba K, Thurlbeck WM. The number and dimensions of small airways in emphysematous lungs. Am J Pathol 1972; 67: 265-75.
33. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-60.
34. Barbee RA, Halonen M, Kaltenborn WT, Burrows B. A longitudinal study of respiratory symptoms in a community population sample. Correlations with smoking, allergen skin-test reactivity, and serum IgE. Chest 1991; 99:20-6.
35. Cullinan P. Persistent cough and sputum: prevalence and clinical characteristics in south east England. Respir Med 1992; 86: 143-9.
36. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med 1969; 280: 397-404.
37. Doherty MJ, Mister R, Pearson MG, Calverley PM. Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease. Thorax 2000; 55:643-9.
38. Power JT, Stewart IC, Connaughton JJ, Brash HM, Shapiro CM, Flenley DC et al. Nocturnal cough in patients with chronic bronchitis and emphysema. Am Rev Respir Dis 1984; 130: 999-1001.
39. Hsu J-Y, Stone RA, Logan-Sinclair R, Worsdell M, Busst C, Chung KF. Coughing frequency in patients with persistent cough using a 24-hour ambulatory recorder. Eur Resp J 1994; 7: 1246-53.
40. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
41. Choudry NB, Fuller RW. Sensitivity of the cough reflex in patients with chronic cough. Eur Respir J 1992; 5:296-300.
42. Doherty MJ, Mister R, Pearson MG, Calverley PM. Capsaicin induced cough in cryptogenic fibrosing alveolitis. Thorax 2000; 55: 1028-32.
43. Bergren DR. Enhanced lung C-fiber responsiveness in sensitized adult guinea pigs exposed to chronic tobacco smoke. J Appl Physiol 2001; 91: 1645-54.
44. Bergren DR. Chronic tobacco smoke exposure increases cough to capsaicin in awake guinea pigs. Respir Physiol 2001; 126: 127-40.
45. Carr MJ, Hunter DD, Undem BJ. Neurotrophins and asthma. Curr Opin Pulm Med 2001; 7: 1-7.
46. Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Nakajima N et al. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Respir Crit Care Med 1995; 151: 613-7.
47. Canning BJ. Interactions between vagal afferent nerve subtypes mediating cough. Pulm Pharmacol Ther 2002; 15: 187-92.
48. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-5.
49. Aikawa T, Shimura S, Sasaki H, Takishima T, Yaegashi H, Takahashi T. Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: 477-82.
50. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55: 635-42.
51. Camner P, Mossberg B, Philipson K. Tracheobronchial clearance and chronic obstructive lung disease. Scand J Respir Dis 1973; 54: 272-81.
52. Wanner A. Clinical aspects of mucociliary transport. Am Rev Respir Dis 1977; 116: 73-125.
53. Smaldone GC, Foster WM, O'Riordan TG, Messina MS, Perry RJ, Langenback EG. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 1993; 103: 1390-6.
54. Foster WM, Langenback EG, Bergofsky EH. Disassociation in the mucociliary function of central and peripheral airways of asymptomatic smokers. Am Rev Respir Dis 1985; 132: 633-9.
55. Rose MC, Gendler SJ. Airway mucin genes and gene products. In: Rogers DF, Lethem MI, eds. Airway Mucus: Basic Mechanisms and Clinical Perspectives. Boston, MA:Birkhauser-Verlag, 1997: 41-66.
56. Hovenberg HW, Davies JR, Carlstedt I. Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem J 1996; 318 (1):319-24.
57. Steiger D, Fahy J, Boushey H, Finkbeiner WE, Basbaum C. Use of mucin antibodies and cDNA probes to quantify hypersecretion in vivo in human airways. Am J Respir Cell Mol Biol 1994; 10: 538-45.
58. Kuo HP, Rohde JAL, Barnes PJ, Rogers DF. Cigarette smoke-induced airway goblet cell secretion: dose dependent differential nerve activation. Am J Physiol 1992; L161-L167.
59. Rogers DF, Aursudkij B, Barnes PJ. Effect of tachykinins on mucus secretion on human bronchi in vitro. Eur J Pharmacol 1989; 174: 283-6.
60. Borchers MT, Wert SE, Leikauf GD. Acrolein-induced MUC5ac expression in rat airways. Am J Physiol 1998; 274: L573-L581.
61. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999; 276: L835-L843.
62. Takeyama K, Dabbagh K, Jeong SJ, Dao-Pick T, Ueki IF, Nadel JA. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 2000; 164: 1546-52.
63. Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst 1998; 90:1198-205.
64. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-505.
65. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al. A controlled trial of sustained- release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-91.
66. Wynder EL, Kaufman PL, Lesser RL. A short-term followup study on ex-cigarette smokers. With special emphasis on persistent cough and weight gain. Am Rev Respir Dis 1967; 96: 645-55.
67. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-9.
68. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:778-84.
69. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19: 209-16.
70. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-21.
71. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-23.
72. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320: 1297-303.
73. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-53.
74. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-9.
75. Calverley PMA, Pauwels RA, Vestbo J, Jones PW, Pride NB, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-56.
76. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32-42.
77. Fahy JV, Boushey HA. Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation. Eur Respir J 1998; 11: 1240-7.
78. Groneberg DA, Eynott PR, Lim S, Oates T, Wu R, Carlstedt I et al. Expression of respiratory mucins in fatal status asthmaticus and mild asthma. Histopathology 2002; 40: 367-73.
79. Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983; 64:405-15.